Please assess the completion status of the following clinical trial:

Trial Title: Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with migraine with or without aura fulfilling the IHS diagnostic criteria 1.1 and 1.2.1 (2004)~* History of migraine of at least 1 year~* Migraine onset before the age of 50 years~* History of 1 - 8 migraine attacks per month~* Male or female patients aged 18 to 65 years~* Female patients of child-bearing potential must be using a highly effective form of contraception (e.g., combined oral contraceptive, IUD, abstinence, vasectomized partner)~* Able and willing to give written informed consent~* Able and willing to complete a migraine diary card to record details of the attack treated with study medication~Exclusion Criteria:~* History of life threatening or intolerable adverse reaction to any triptan~* Use of prescription migraine prophylactic drugs within 15 days (30 days for flunarizine) prior to Screening Visit and during study participation~* Using herbal preparations (e.g., feverfew, butterbur) for migraine prophylaxis~* Using 5-HT reuptake inhibitors~* Using drugs known to inhibit CYP450 enzymes (see Appendix 2 for details)~* Pregnant or breast-feeding women~* Women of child-bearing potential not using highly effective contraception~* History or evidence of coronary artery disease, ischemic or hemorrhagic stroke, epilepsy or any other condition placing the patient at increased risk of seizures~* History of hypertension (controlled or uncontrolled)~* History of orthostatic hypotension~* Current use of hemodynamically active cardiovascular drugs~* History within the previous 3 years or current evidence of abuse of any drug, prescription or illicit, or alcohol~* Significant renal or hepatic impairment~* Previous participation in this clinical trial~* Participation in any clinical trial of an experimental drug or device in the previous 30 days~* Any medical condition or laboratory test which in the judgment of the investigator makes the patient unsuitable for the study~* Known Hepatitis B or C or HIV infection~* Patients who are employees of the sponsor~* Relatives of, or staff directly reporting to, the investigator~* Patients with known hypersensitivity to COL-144, other 5HT1F receptor agonists or to any excipient of COL-144 drug product~* Patients who were treated with study medication in the COL MIG-201 study (Patients screened but not treated under that protocol are not excluded)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 50 mg Lasmiditan (Type: EXPERIMENTAL): 50 mg lasmiditan administered orally (PO)
- 100 mg Lasmiditan (Type: EXPERIMENTAL): 100 mg lasmiditan administered orally (PO)
- 200 mg Lasmiditan (Type: EXPERIMENTAL): 200 mg lasmiditan administered orally (PO)
- 400 mg Lasmiditan (Type: EXPERIMENTAL): 400 mg lasmiditan administered orally (PO)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally (PO)

Based on this trial design, predict the completion outcome and termination type (if applicable).